Navigation Links
Data Published in Anticancer Research Show ChemoFx(R) Assay Results Correlate With Outcomes in Breast Cancer
Date:7/1/2008

Ability to Perform Testing on Biopsy-sized Specimens Allows for Greater

Clinical Utility in all Breast Cancer Settings

PITTSBURGH, July 1 /PRNewswire/ -- Precision Therapeutics Inc. announced today that results from the ChemoFx(R) Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlate with pathologic complete response in breast cancer patients treated with neoadjuvant (pre-operative) chemotherapy. Data published in Anticancer Research show that the assay accurately predicted response to therapy 75% of the time. This study, done in conjunction with US Oncology, a leading cancer research and treatment network, represents the company's first publication in the breast cancer setting.

"Achieving pathologic complete response is an important goal for patients in the neoadjuvant breast cancer setting. Precision Therapeutics' data demonstrate that ChemoFx has the potential to predict which chemotherapy regimens will be most effective, thus potentially sparing patients from unnecessary toxicity associated with ineffective treatment," said Joyce O'Shaughnessy, MD, of Baylor-Sammons Cancer Center in Dallas and associate study investigator. Ongoing definitive trials are evaluating whether the promising results from our study with ChemoFx will help us design more personalized pre-operative treatment strategies."

Other major findings of the study addressed technical aspects of the assay, including the feasibility of performing the test on small amounts of tissue and the reproducibility of test results. The study demonstrated that the test could be successfully performed 84% of the time on tissue samples as small as 35 mg (2 14 gauge core needle biopsies). This finding is significant because historically chemoresponse assays have been limited by the need for a large amount of tissue (1-5 grams). The small tissue requirement demonstrated in this study is crucial in the breast cancer setting, as the diagnosis is often made by biopsy. The reproducibility of the test was also confirmed in this study, showing that chemoresponse profiles had a coefficient of variation <3%.

"We are excited to publish our first results in breast cancer that are tied to patient outcomes. These findings further validate the use of the ChemoFx assay to assist in selection of therapy for cancer patients," said Precision Therapeutics CEO Sean McDonald.

About the study

Tissue specimens were obtained from a subset of patients (N=34) enrolled in the US Oncology 02-103 trial between April 2005 and April 2006. The study was a Phase II trial of patients with locally advanced stage II and III breast cancer treated with four cycles of preoperative therapy consisting of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by four cycles of docetaxel with capecitabine. HER-2 positive patients also received Herceptin. The final manuscript for 02-103 is pending.

About ChemoFx(R)

ChemoFx is a decision support tool that measures a specific patient's tumor response to various types, combinations and doses of chemotherapy selected by the patient's physician. The laboratory test examines how many cancer cells are killed after exposure to treatment, using a patient's living cancer cells that have been removed during a biopsy, aspiration or surgical procedure. ChemoFx can be tested in all solid tumor types and may be used in primary, recurrent, and metastatic tumors.

About Precision Therapeutics

Precision Therapeutics is an oncology services company dedicated to the individualization of cancer therapy. Precision Therapeutics is a leader in the development and delivery of personalized treatment support tools that assist physicians and benefit cancer patients. For more information visit http://www.precisiontherapeutics.com, call 800-547-6165 or email info@ptilabs.com.

Contact:

Heather Theoret Rockwell

Precision Therapeutics Inc.

412-432-1500 ext. 1589

hrockwell@ptilabs.com


'/>"/>
SOURCE Precision Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Two studies published in the Lancet
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. New report on mobile phone research published
5. 2007/2008 Pharmaceutical R&D Factbook Published by CMR International is Now Available
6. Meta-Analysis of Blood Phe Levels and Clinical Outcomes in PKU Published
7. Clinical Study Published Showing Benefits of Glue Used in Facelift Surgery
8. New tool to assess excessive daytime sleepiness in adolescents published in JCSM
9. Published Results Using AtriCure Minimally Invasive Products
10. Mirixa Debuts RxFYI - a Free Pharmacy-Published Health eNewsletter Building Patient Loyalty and Generating Revenue
11. Long Term Care Newsletter Debuts, Published by LTC Financial Partners; Advice on Living Better, Not Just Longer, With Financial Protection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... LARKR™ , an innovative new smartphone app ... across the country to join its online treatment platform. , Launching in just ... a substantially greater number of people in need nationwide, and to supplement their traditional ...
(Date:6/26/2017)... ... June 26, 2017 , ... New patients with missing teeth ... with or without a referral. Dr. Cotey is a trusted dentist who has placed ... replacement option. , Patients with missing teeth in Fitchburg, WI, are encouraged to find ...
(Date:6/25/2017)... , ... June 25, 2017 , ... Republicans in the ... and replace Obamacare, called the Better Care Reconciliation Act. It differs significantly from the ... will need to be reconciled in committee, or the House will have to take ...
(Date:6/25/2017)... ... ... heatwave currently bearing down on Northern California pushing temperatures to the maximum, many people are ... with laser hair removal. , The process of summer waxing and constantly shaving unwanted ... want to do is get out, dive in and cool off. There is a way ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... PA at the Sheraton Erie Bayfront and Erie Convention Center on June 8-10. ... experience, exhibits, a student quiz bowl, award and scholarship presentations, and professional networking. ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... CAESAREA, Israel , May 30, 2017 DarioHealth Corp. ... and big data solutions, today announced that it will be presenting ... 2017, at 8:00 AM PT. Erez Raphael , CEO, of ... The conference will be held on June 6th & 7th, ... 180 companies in the small / micro-cap space. ...
(Date:5/26/2017)... plc (NASDAQ: ENDP ) announced today that ... in a fireside chat at Goldman Sachs, 38 th ... 10:40 a.m. PT / 1:40 p.m. ET. The conference will ... Verdes, CA. A live webcast and ... Company,s website at http://www.endo.com/investors/overview . Participants should allow approximately ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
Breaking Medicine Technology: